Mithra Pharmaceuticals SA

BATS-CHIXE:MITRAb Stock Report

Market Cap: €100.9m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Mithra Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 1/6

Mithra Pharmaceuticals has a total shareholder equity of €-8.7M and total debt of €266.1M, which brings its debt-to-equity ratio to -3048.5%. Its total assets and total liabilities are €374.7M and €383.5M respectively.

Key information

-3,048.5%

Debt to equity ratio

€266.14m

Debt

Interest coverage ration/a
Cash€23.71m
Equity-€8.73m
Total liabilities€383.47m
Total assets€374.74m

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: MITRAb has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: MITRAb has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: MITRAb has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: MITRAb's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MITRAb has sufficient cash runway for 10 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: Insufficient data to determine if MITRAb has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies